ArticleBlood research2014
Hereditary hemorrhagic telangiectasia treated with low dose intravenous bevacizumab.
Article in Blood research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Efficacy of bevacizumab in hereditary hemorrhagic telangiectasia: a systematic review and network meta-analysis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025Pooled it
- Bevacizumab as Rescue Therapy for GI Bleeding in Hereditary Hemorrhagic Telangiectasia.Cureus · 2026Article
- Long-term bevacizumab is safe and effective in managing small bowel angioectasias bleeding refractory to conventional treatments: a case report.Gastroenterology report · 2024Article
- Diagnostic yield of capsule endoscopy for small bowel arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia: a systematic review and meta-analysis.Endoscopy international open · 2019Article
- [Gene identification in a family of hereditary hemorrhagic telangiectasia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2018Article
- Bevacizumab for Refractory Gastrointestinal Bleeding in Rendu-Osler-Weber Disease.GE Portuguese journal of gastroenterology · 2018Article
- Efficacy and safety of bevacizumab treatment for refractory brain edema: Case report.Medicine · 2017Article
- Nintedanib as a novel treatment option in hereditary haemorrhagic telangiectasia.BMJ case reports · 2017Article
- Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A case report.Wiener klinische Wochenschrift · 2017Article
- Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients.PloS one · 2017Observational
- Bevacizumab and gastrointestinal bleeding in hereditary hemorrhagic telangiectasia.World journal of gastrointestinal surgery · 2016Article
- Current status of familial gastrointestinal polyposis syndromes.World journal of gastrointestinal oncology · 2015Review
- Bevacizumab to Treat Cholangiopathy in Hereditary Hemorrhagic Telangiectasia: Be Cautious: A Case Report.Medicine · 2015Article
- Intravenous Bevacizumab Therapy in a Patient with Hereditary Hemorrhagic Telangiectasia,Case reports in gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder that leads to mucocutaneous telangiectasias, epistaxis, and gastrointestinal bleeding. Depending on the severity and manifestation of the disease, various therapeutic modalities have been used, from local bleeding control to surgery or concomitant drug therapy. Several articles under review have presented guidelines for treatment of HHT with bevacizumab as a direct anti-angiogenesis strategy. Still, neither the exact optimal dose nor the minimum effective dose of intravenous bevacizumab in patients with severe HHT has been reported. A 55-year-old man presented with long-standing epistaxis, recent melena, dizziness, and a three-generation family history of chronic epistaxis, anemia, and regular blood transfusions. Treatment with argon plasma coagulation (APC) for the gastrointestinal bleeding failed to raise hemoglobin levels, we considered using the bevacizumab. We report a patient with severe HHT, who was treated with low-dose bevacizumab (2 mg/kg) and improved substantially.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.